RxDoctor Payments Data

Mobeen Choudhri, MD

Interventional Pain Medicine · Bellaire, TXNPI 1942347877

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $50,179 of the $60,591 with a category attached, or 82.8%. 56 manufacturers reported payments, led by Medtronic at 39.7% of the total. Reporting peaked in 2019 at $14,815 and has fallen 56.8% since, to $6,395 in 2025. Among interventional pain medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$60,591in general payments, 2019–2025

Across 1,452 payments — averaging $41.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$24K
  • Si-bone, Inc.$7K
  • Boston Scientific$6K
  • Abbott$4K
  • Nevro Corp.$2K
  • Saluda Medical Americas, Inc.$2K
  • plus $15K from 50 others

What the payments were for

  • Travel & lodging$10,35317%
  • Food & beverage$50,17983%
  • Education$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(3 entities)439$24,048
Si-bone, Inc.72$6,666
Boston Scientific135$6,143
Abbott145$4,351
Nevro Corp.40$2,132
Saluda Medical Americas, Inc.17$2,116
AbbVie(2 entities)100$1,819
Relievant Medsystems, Inc.11$1,228
SPR Therapeutics, Inc8$1,117
Vertos Medical, Inc.22$987
Teva Pharmaceuticals USA, Inc.38$937
Biotronik NRO, Inc.37$886
Pfizer65$846
Collegium Pharmaceutical, Inc.46$574
Amgen(2 entities)20$563
Nalu Medical, Inc.11$535
Pacira Pharmaceuticals Incorporated6$530
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC29$498
Scilex Pharmaceuticals Inc.18$393
Lilly USA, LLC22$327
Eisai Inc.18$322
Stryker3$281
Merz North America, Inc.9$262
Daiichi Sankyo Inc.14$220
Bioventus LLC3$201
Biodelivery Sciences International, Inc.15$199
Lundbeck LLC8$190
Novartis13$184
Averitas Pharma Inc.8$166
Merz Pharmaceuticals, LLC8$158
Arbor Pharmaceuticals, Inc.9$158
Zynex Medical, Inc.1$155
Globus Medical2$132
Biohaven Pharmaceutical Holding Company Ltd.7$119
Foundation Fusion Solutions, LLC1$110
Electronic Waveform Lab, Inc.1$104
Tersera Therapeutics LLC6$98
Painteq LLC3$96
Fujifilm Sonosite, Inc.1$95
Pacira Therapeutics, Inc.4$73
Takeda Pharmaceuticals U.S.A., Inc.6$66
Idorsia Pharmaceuticals US Inc4$65
Zyla Life Sciences, Inc.3$51
MDD US Operations, LLC3$47
Fidia Pharma USA Inc.2$42
AstraZeneca3$41
Supernus Pharmaceuticals, Inc.2$39
Assertio Therapeutics, Inc.2$38
Inspire Medical Systems, Inc.1$31
Tactile Systems Technology Inc2$30
Impel Pharmaceuticals Inc.2$30
Bausch Health US, LLC2$29
GRT US Holding, Inc.2$24
Shionogi Inc1$19
Vertiflex, Inc.1$11
Biocomposites Inc1$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,591 in reported general payments places this provider in the 90th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$2,150,786
Medicare patients
418
Services billed
6,726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina59$103,380
Xtampza ErOxycodone Myristate102$72,380
BelbucaBuprenorphine Hcl84$66,355
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,502$28,259
Nucynta ErTapentadol Hcl16$17,462
Fentanyl148$17,311
Morphine Sulfate ErMorphine Sulfate357$11,082
Buprenorphine25$6,501
Buprenorphine Hcl176$4,142
Gabapentin252$4,092
Lidocaine29$3,622
Pregabalin148$3,501
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen193$3,123
Oxycodone Hcl199$3,123
Tizanidine Hcl317$2,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er$574$156,197202 claims
AbbVieBotox$1,819$103,38059 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Bellaire

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →